Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$19.4MCash on Hand
9.6mo Cash Runway
Follow SER by emailGet an email when SER reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SER, unsubscribe in one click. Privacy
📣 What SER Says Is Next
first half of 2027 · “The trial continues to assess safety, tolerability, pharmacokinetics and exploratory clinical measures of motor function, with topline data from the single-ascending-dose portion expected in the first half of 2027.”
Company press release, Nov 12, 2026 · SEC filing
first half of 2027 · “The Company expects to report topline data from the single-ascending-dose portion of the study in the first half of 2027.”
Company press release, Sep 9, 2026 · SEC filing
first half of 2027 · “Top-line data from the single-ascending-dose arm remain targeted for the first half of 2027.”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Reported Q3 2026 net loss of $7.9 million, or $(0.31) per share, versus $4.7 million, or $(0.45), a year earlier. R&D rose to $4.6 million. Cash and equivalents were $19.4 million as of September 30, 2026. Dosing began in Cohort 2 of SER-252 after the safety committee recommended advancement. Form 8-K · SEC filing · Press release
Sep 9, 2026 ·
Clinical trial Blinded review of Cohort 1 in the Phase 1b SER-252 study in advanced Parkinson's disease led the independent safety committee to recommend advancing to Cohort 2. Blinded Cohort 1 showed a pharmacokinetic profile consistent with sustained apomorphine exposure. Form 8-K · SEC filing · Press release
Aug 27, 2026 ·
Financing Serina entered a common stock purchase agreement with Roth Principal Investments allowing it to sell up to $25,000,000 of new common stock over up to 36 months, at the company's sole discretion. Sales are subject to a Threshold Price and a registration statement being declared effective. Form 8-K · SEC filing
Aug 24, 2026 ·
Financing Serina Therapeutics filed a registration statement for up to 12,500,000 shares of common stock to be sold by Roth Principal Investments under a Common Stock Purchase Agreement dated August 21, 2026, under which the company may receive up to $25,000,000 in gross proceeds at its discretion. Form S-1 · SEC filing
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 13, 2026 ·
Earnings Serina reported Q2 2026 net loss of $8.9 million, or $(0.55) per share, versus $6.6 million, or $(0.66), a year earlier. R&D rose to $3.8 million and G&A to $3.0 million. Cash and equivalents were $23.0 million as of June 30, 2026. Cohort 1 of the SER-252 study finished dosing in July. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2027 · Phase 1 · Recruiting · SAD Study in Patients With Parkinson's Disease and Motor Fluctuations Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
SER holds $19.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $6.1M/quarter from operations,
an estimated runway of 9.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:90 · High
Cash runway 10 months +30
ATM program on file since Apr 2025 +15
Shelf registration (S-3, Apr 2025) +10
Going-concern doubt in the latest 10-Q +15As such, there is substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Share count 26,569,458 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SER picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SER and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.